AQR Capital Management
SUPN icon

AQR Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

AQR Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.08M Sell
98,257
-27,973
-22% -$1.42M ﹤0.01% 1738
2025
Q4 		$6.27M Sell
126,230
-10,197
-7% -$496K ﹤0.01% 1437
2025
Q3 		$6.52M Sell
136,427
-4,130
-3% -$166K ﹤0.01% 1301
2025
Q2 		$4.43M Buy
140,557
+55,333
+65% +$1.77M ﹤0.01% 1353
2025
Q1 		$2.79M Buy
85,224
+22,182
+35% +$786K ﹤0.01% 1426
2024
Q4 		$2.28M Buy
63,042
+3,231
+5% +$114K ﹤0.01% 1463
2024
Q3 		$1.86M Buy
59,811
+45,857
+329% +$1.43M ﹤0.01% 1541
2024
Q2 		$373K Buy
13,954
+219
+2% +$6.35K ﹤0.01% 2184
2024
Q1 		$469K Sell
13,735
-3,690
-21% -$110K ﹤0.01% 1978
2023
Q4 		$504K Buy
17,425
+4,129
+31% +$109K ﹤0.01% 1876
2023
Q3 		$367K Buy
13,296
+2,648
+25% +$80.6K ﹤0.01% 1954
2023
Q2 		$320K Buy
10,648
+110
+1% +$3.85K ﹤0.01% 1917
2023
Q1 		$382K Sell
10,538
-905
-8% -$34.8K ﹤0.01% 1866
2022
Q4 		$408K Buy
11,443
+3,229
+39% +$112K ﹤0.01% 1881
2022
Q3 		$278K Buy
8,214
+468
+6% +$15.2K ﹤0.01% 1967
2022
Q2 		$224K Buy
+7,746
New +$222K ﹤0.01% 1960
2021
Q4 		– Sell
-8,887
Closed -$237K – 2275
2021
Q3 		$237K Buy
+8,887
New +$239K ﹤0.01% 2105
2021
Q2 		– Sell
-8,942
Closed -$234K – 2297
2021
Q1 		$234K Sell
8,942
-39,385
-81% -$1.1M ﹤0.01% 2069
2020
Q4 		$1.22M Sell
48,327
-19,374
-29% -$417K ﹤0.01% 1413
2020
Q3 		$1.41M Sell
67,701
-16,034
-19% -$364K ﹤0.01% 1259
2020
Q2 		$1.99M Buy
83,735
+38,925
+87% +$860K ﹤0.01% 1169
2020
Q1 		$806K Buy
+44,810
New +$942K ﹤0.01% 1422
2019
Q4 		– Sell
-14,950
Closed -$411K – 2176
2019
Q3 		$411K Sell
14,950
-5,300
-26% -$157K ﹤0.01% 1815
2019
Q2 		$670K Buy
20,250
+5,026
+33% +$172K ﹤0.01% 1633
2019
Q1 		$533K Buy
15,224
+175
+1% +$6.51K ﹤0.01% 1781
2018
Q4 		$500K Sell
15,049
-17,617
-54% -$758K ﹤0.01% 1780
2018
Q3 		$1.65M Sell
32,666
-51,650
-61% -$2.55M ﹤0.01% 1480
2018
Q2 		$5.05M Sell
84,316
-49,072
-37% -$2.54M 0.01% 1022
2018
Q1 		$6.11M Buy
133,388
+49,097
+58% +$2.05M 0.01% 921
2017
Q4 		$3.36M Sell
84,291
-3,338
-4% -$132K ﹤0.01% 1172
2017
Q3 		$3.5M Buy
87,629
+1,265
+1% +$54.7K ﹤0.01% 1171
2017
Q2 		$3.72M Sell
86,364
-3,802
-4% -$135K ﹤0.01% 1144
2017
Q1 		$2.82M Buy
90,166
+8,672
+11% +$232K ﹤0.01% 1234
2016
Q4 		$2.06M Sell
81,494
-23,912
-23% -$534K ﹤0.01% 1387
2016
Q3 		$2.61M Sell
105,406
-43,750
-29% -$990K ﹤0.01% 1291
2016
Q2 		$3.04M Sell
149,156
-21,914
-13% -$389K 0.01% 1112
2016
Q1 		$2.61M Buy
171,070
+24,740
+17% +$323K ﹤0.01% 1130
2015
Q4 		$1.97M Sell
146,330
-65,709
-31% -$1.02M ﹤0.01% 1248
2015
Q3 		$2.98M Buy
212,039
+55,093
+35% +$1.02M 0.01% 971
2015
Q2 		$2.67M Buy
156,946
+23,475
+18% +$334K 0.01% 1058
2015
Q1 		$1.61M Sell
133,471
-49,700
-27% -$470K ﹤0.01% 1198
2014
Q4 		$1.52M Buy
183,171
+106,571
+139% +$895K ﹤0.01% 1434
2014
Q3 		$666K Sell
76,600
-14,600
-16% -$132K ﹤0.01% 1822
2014
Q2 		$999K Buy
+91,200
New +$812K ﹤0.01% 1650

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's SUPN Position: Q1 2026 in Review

AQR Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 22% in Q1 2026, selling an estimated $1.42M and leaving 98,257 shares worth $5.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

AQR Capital Management first reported a position in SUPN in Q2 2014 and has held it in 44 quarters since. The position peaked at $6.52M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • AQR Capital Management held 98,257 shares of Supernus Pharmaceuticals worth $5.08M as of Q1 2026.
  • AQR Capital Management sold 27,973 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.42M.
  • Supernus Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1738 holding.
  • AQR Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2014 and has held it in 44 quarters since.
  • AQR Capital Management's Supernus Pharmaceuticals position peaked at $6.52M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.